[go: up one dir, main page]

PE20091016A1 - Compuestos de bencensulfonanilida apropiados para tratar trastornos que responden a la modulacion del receptor de serotonina 5-ht - Google Patents

Compuestos de bencensulfonanilida apropiados para tratar trastornos que responden a la modulacion del receptor de serotonina 5-ht

Info

Publication number
PE20091016A1
PE20091016A1 PE2008001857A PE2008001857A PE20091016A1 PE 20091016 A1 PE20091016 A1 PE 20091016A1 PE 2008001857 A PE2008001857 A PE 2008001857A PE 2008001857 A PE2008001857 A PE 2008001857A PE 20091016 A1 PE20091016 A1 PE 20091016A1
Authority
PE
Peru
Prior art keywords
bencensulfonanilide
serotonin
compounds suitable
treating disorders
receptor modulation
Prior art date
Application number
PE2008001857A
Other languages
English (en)
Inventor
Wilfried Martin Braje
Sean Colm Turner
Andreas Haupt
Udo Lange
Karla Drescher
Karsten Wicke
Liliane Unger
Mario Mezler
Wolfgang Wernet
Matthias Mayrer
Ana-Lucia Jongen-Relo
Anton Bespalov
Min Zhang
Original Assignee
Abbott Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40340548&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20091016(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Gmbh & Co Kg filed Critical Abbott Gmbh & Co Kg
Publication of PE20091016A1 publication Critical patent/PE20091016A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)

Abstract

REFERIDA A COMPUESTOS DERIVADOS BENCENSULFONANILIDA DE FORMULAS (I) Y (I') DONDE R1 Y R2 SON CADA UNO H, CH3; R2 ES H, METILO; R3 ES H, FLUOR-ALCOXI C1-C2, ALCOXI C1-C2 FLUORADO; R4 ES H, ALQUILO C1-C4, ALQUILO C1-C4 FLUORADO; R5 ES H, F, ALQUILO C1-C2, ENTRE OTROS; R6 ES H, F, Cl. SON COMPUESTOS SELECCIONADOS: CLORHIDRATO DE 3-DIFLUOROMETOXI-N-(4-METOXI-3-PIPERAZIN-1-IL-FENIL)-BENCENSULFONAMIDA; CLORHIDRATO DE 4-DIFLUOROMETOXI-N-(4-METOXI-3-PIPERAZIN-1-IL-FENIL)-BENCENSULFONAMIDA; ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON MODULADORES DE RECEPTOR DE SEROTONINA 5-HT6, UTILES PARA EL TRATAMIENTO DE ENFERMEDAD DE ALZHEIMER, ESQUIZOFRENIA, OBESIDAD, ENTRE OTROS
PE2008001857A 2007-11-02 2008-10-30 Compuestos de bencensulfonanilida apropiados para tratar trastornos que responden a la modulacion del receptor de serotonina 5-ht PE20091016A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US165607P 2007-11-02 2007-11-02

Publications (1)

Publication Number Publication Date
PE20091016A1 true PE20091016A1 (es) 2009-08-15

Family

ID=40340548

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001857A PE20091016A1 (es) 2007-11-02 2008-10-30 Compuestos de bencensulfonanilida apropiados para tratar trastornos que responden a la modulacion del receptor de serotonina 5-ht

Country Status (22)

Country Link
US (2) US7790727B2 (es)
EP (1) EP2217583B1 (es)
JP (1) JP2011502973A (es)
KR (1) KR20100100849A (es)
CN (1) CN101918384A (es)
AR (1) AR069151A1 (es)
AT (1) ATE535517T1 (es)
AU (1) AU2008320821A1 (es)
BR (1) BRPI0819233A2 (es)
CA (1) CA2704529A1 (es)
CL (1) CL2008003232A1 (es)
ES (1) ES2378596T3 (es)
IL (1) IL205469A0 (es)
MX (1) MX2010004832A (es)
NZ (1) NZ585087A (es)
PA (1) PA8802201A1 (es)
PE (1) PE20091016A1 (es)
RU (1) RU2010122300A (es)
TW (1) TW200927117A (es)
UY (1) UY31447A1 (es)
WO (1) WO2009056632A1 (es)
ZA (1) ZA201003594B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2008003232A1 (es) * 2007-11-02 2009-11-27 Abbott Gmbh & Co Kg Compuestos derivados de bencensulfonanilida; composición farmacéutica que los comprende; y uso en el tratamiento de enfermedades del sistema nervioso central, disfunciones cognitivas, esquizofrenia, enfermedades adictivas, enfermedad de alzheimer u obesidad.
MX2011011519A (es) * 2009-04-30 2012-01-30 Abbott Gmbh & Co Kg Compuestos de bencensulfonanilida adecuados para tratar trastornos que responden a la modulacion del receptor de serotonina 5-ht6.
EP3134392B1 (en) 2014-04-19 2019-01-02 Sunshine Lake Pharma Co., Ltd. Sulfonamide derivatives and pharmaceutical applications thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DZ2376A1 (fr) * 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
GB9818914D0 (en) * 1998-08-28 1998-10-21 Smithkline Beecham Plc Use
GB9818916D0 (en) * 1998-08-28 1998-10-21 Smithkline Beecham Plc Use
SE0002739D0 (sv) * 2000-07-21 2000-07-21 Pharmacia & Upjohn Ab New use
AU2005266448A1 (en) * 2004-07-28 2006-02-02 Glaxo Group Limited Piperazine derivatives useful for the treatment of gastrointestinal disorders
CL2008003232A1 (es) * 2007-11-02 2009-11-27 Abbott Gmbh & Co Kg Compuestos derivados de bencensulfonanilida; composición farmacéutica que los comprende; y uso en el tratamiento de enfermedades del sistema nervioso central, disfunciones cognitivas, esquizofrenia, enfermedades adictivas, enfermedad de alzheimer u obesidad.

Also Published As

Publication number Publication date
AR069151A1 (es) 2009-12-30
US7790727B2 (en) 2010-09-07
EP2217583A1 (en) 2010-08-18
JP2011502973A (ja) 2011-01-27
KR20100100849A (ko) 2010-09-15
NZ585087A (en) 2012-06-29
ATE535517T1 (de) 2011-12-15
CL2008003232A1 (es) 2009-11-27
AU2008320821A1 (en) 2009-05-07
IL205469A0 (en) 2010-12-30
CN101918384A (zh) 2010-12-15
ES2378596T3 (es) 2012-04-16
WO2009056632A1 (en) 2009-05-07
TW200927117A (en) 2009-07-01
US20090131452A1 (en) 2009-05-21
CA2704529A1 (en) 2009-05-07
MX2010004832A (es) 2010-10-20
EP2217583B1 (en) 2011-11-30
BRPI0819233A2 (pt) 2017-05-02
PA8802201A1 (es) 2009-06-23
RU2010122300A (ru) 2011-12-10
ZA201003594B (en) 2011-02-23
UY31447A1 (es) 2009-05-29
US20110086863A1 (en) 2011-04-14

Similar Documents

Publication Publication Date Title
PE20090890A1 (es) Compuestos derivados de 1-(2,3-dihidrobenzo[1,4]dioxin-2-ilmetil)azaciclos como antagonistas del suptipo adrenoreceptor alfa2c
AR070395A1 (es) Derivados de 4,5-dihidro-oxazol-2-il- amina
PE20160844A1 (es) Compuestos triciclicos como agentes anticancerigenos
PE20091204A1 (es) Derivados de 2-aminoquinolina como antagonistas del receptor de 5-ht5a
PE20090622A1 (es) Nuevos derivados de bencimidazol sustituido
PE20120113A1 (es) Nuevos derivados de benzotiadiazepinas, su procedimiento de preparacion y composiciones farmaceuticas que los contienen
AR078756A1 (es) Moduladores alostericos positivos (map)
PE20120881A1 (es) Compuestos de n-fenil-(piperazinil u homopiperazinil)-bencensulfonamida o bencensulfonil-fenil-(piperazina u homopiperazina) como moduladores del receptor de serotonina 5-ht6
AR066509A1 (es) Derivados de tiazol, medicamentos que los contienen, proceso de preparacion y usos como moduladores de beta amiloide.
PE20180500A1 (es) Derivados de 2,3-dihidro-4h-1,3-benzoxazin-4-ona como moduladores del receptor muscarinico colinergico m1
PE20081462A1 (es) Bifenilsulfonilos y fenil heteroaril sufonilos como moduladores del receptor h3 de histamina utiles para el tratamiento de los trastornos relacionados con dicho receptor
AR069607A1 (es) Inhibidores de la estearoil-coa desaturasa
AR059328A1 (es) Derivados de antranilamida-2-amino-heteroareno-carboxamida, un proceso para su obtencion, composiciones farmaceuticas que los contienen y el uso de estos compuestos para la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por cetp
ATE430744T1 (de) Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren
PE20141000A1 (es) Ureas asimetricas y usos medicos de las mismas
PE20091080A1 (es) 2-[3-(2,2-difluoro-benzo[1,3]dioxol-5-ilamino)-5-(2,6-dimetil-piridin-4-il)-[1,2,4]triazol-1-il]-n-etil-acetamida y sus sales como moduladores de los receptores nicotinicos alfa 7
AR054786A1 (es) (6-fluor-benzol(1,3) dioxolil)-morfolin-4-il-metanomas, moduladoras del receptor cb1
PE20090655A1 (es) Derivados de 2-aza-biciclo[2.2.2]octano para prevencion o tratamiento de psicosis
AR059076A1 (es) Tiofenil y pirrolil azepinas como ligandos del receptor 5-ht2c de serotonina y usos de las mismas
PE20090999A1 (es) Nuevos derivados de metil-bencimidazol
PE20090295A1 (es) Derivados de espirociclopropilpiperidina
PE20080941A1 (es) Compuestos triciclicos como agonistas del receptor de melatonina
PE20080191A1 (es) Compuestos heterociclicos apropiados para tratar trastornos que responden a la modulacion del receptor de serotonina 5ht6
PE20090988A1 (es) Derivados de indol-2-ona como antagonistas del receptor de la grelina
PE20040763A1 (es) Derivados de aminoalcoxiindoles como ligandos de los receptores 5-ht6

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed